Biomerica (BMRA) Competitors $3.38 -0.05 (-1.46%) As of 10:48 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. LVTX, SCYX, TPST, KZR, FGEN, RANI, GRCE, ALXO, PULM, and COEPShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include LAVA Therapeutics (LVTX), SCYNEXIS (SCYX), Tempest Therapeutics (TPST), Kezar Life Sciences (KZR), FibroGen (FGEN), Rani Therapeutics (RANI), Grace Therapeutics (GRCE), ALX Oncology (ALXO), Pulmatrix (PULM), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Its Competitors LAVA Therapeutics SCYNEXIS Tempest Therapeutics Kezar Life Sciences FibroGen Rani Therapeutics Grace Therapeutics ALX Oncology Pulmatrix Coeptis Therapeutics Biomerica (NASDAQ:BMRA) and LAVA Therapeutics (NASDAQ:LVTX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, community ranking, earnings and dividends. Do analysts recommend BMRA or LVTX? LAVA Therapeutics has a consensus target price of $3.17, suggesting a potential upside of 141.73%. Given LAVA Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe LAVA Therapeutics is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00LAVA Therapeutics 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility & risk, BMRA or LVTX? Biomerica has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, LAVA Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500. Is BMRA or LVTX more profitable? LAVA Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -100.52%. LAVA Therapeutics' return on equity of -62.22% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-100.52% -90.19% -64.54% LAVA Therapeutics N/A -62.22%-29.37% Do institutionals and insiders hold more shares of BMRA or LVTX? 22.3% of Biomerica shares are held by institutional investors. 15.0% of Biomerica shares are held by insiders. Comparatively, 9.5% of LAVA Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in BMRA or LVTX? Biomerica received 112 more outperform votes than LAVA Therapeutics when rated by MarketBeat users. Likewise, 67.82% of users gave Biomerica an outperform vote while only 64.10% of users gave LAVA Therapeutics an outperform vote. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% LAVA TherapeuticsOutperform Votes2564.10% Underperform Votes1435.90% Which has preferable earnings and valuation, BMRA or LVTX? Biomerica has higher revenue and earnings than LAVA Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than LAVA Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.68M1.52-$5.98M-$2.32-1.46LAVA Therapeutics$4.99M6.91-$41.97M-$1.04-1.26 Does the media refer more to BMRA or LVTX? In the previous week, Biomerica had 3 more articles in the media than LAVA Therapeutics. MarketBeat recorded 5 mentions for Biomerica and 2 mentions for LAVA Therapeutics. LAVA Therapeutics' average media sentiment score of 1.43 beat Biomerica's score of 0.69 indicating that LAVA Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Biomerica Positive LAVA Therapeutics Positive SummaryLAVA Therapeutics beats Biomerica on 10 of the 17 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.61M$2.70B$5.60B$8.62BDividend YieldN/A0.70%5.28%4.18%P/E Ratio-9.947.8227.2320.02Price / Sales1.5235.07417.65154.33Price / CashN/A15.7538.2534.64Price / Book8.675.537.124.70Net Income-$5.98M-$65.73M$3.23B$247.97M7 Day Performance4.32%1.23%2.74%2.64%1 Month Performance-4.79%0.61%8.94%6.39%1 Year Performance-27.16%-21.04%31.59%13.95% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.3683 of 5 stars$3.38-1.5%N/A-26.1%$8.61M$5.68M-9.9460Short Interest ↑Gap UpLVTXLAVA Therapeutics2.4986 of 5 stars$1.36+3.0%$3.17+132.8%-42.2%$34.72M$4.99M-1.3260Positive NewsSCYXSCYNEXIS0.8887 of 5 stars$0.86-6.3%N/A-60.0%$33.56M$2.63M-1.1660Positive NewsTPSTTempest Therapeutics2.5477 of 5 stars$8.95+8.5%$30.00+235.2%-81.5%$32.95MN/A-5.8520News CoverageGap UpHigh Trading VolumeKZRKezar Life Sciences4.5772 of 5 stars$4.45+1.1%$39.50+787.6%-33.8%$32.51M$7M-0.3460FGENFibroGen4.5607 of 5 stars$0.32+2.0%$10.00+3,029.9%-72.7%$32.28M$7.00M-0.26570RANIRani Therapeutics2.0098 of 5 stars$0.57+2.5%$9.40+1,537.3%-85.7%$32.19M$1.20M-0.54110GRCEGrace Therapeutics2.7894 of 5 stars$3.16+6.4%$12.00+279.7%N/A$32.04MN/A-2.72N/APositive NewsHigh Trading VolumeALXOALX Oncology2.705 of 5 stars$0.58-0.1%$3.30+470.2%-93.6%$30.90MN/A-0.1940News CoverageAnalyst RevisionGap UpPULMPulmatrix0.4346 of 5 stars$8.44-5.1%N/A+334.2%$30.81M$1.92M-3.2020Gap DownCOEPCoeptis Therapeutics1.4063 of 5 stars$8.75-2.2%N/A+49.6%$30.75M$62.87K-1.512Positive News Related Companies and Tools Related Companies LAVA Therapeutics Alternatives SCYNEXIS Alternatives Tempest Therapeutics Alternatives Kezar Life Sciences Alternatives FibroGen Alternatives Rani Therapeutics Alternatives Grace Therapeutics Alternatives ALX Oncology Alternatives Pulmatrix Alternatives Coeptis Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BMRA Stock Free BMRA Stock Alerts